文献速递炎症性肠病

托法替布治疗溃疡性结肠炎:荷兰ICC前瞻性登记研究结果

Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry.
PubMed 文献 · Aliment Pharmacol Ther · 2020-04-01

该研究在荷兰15家医院前瞻性纳入123例启动托法替布的溃疡性结肠炎患者,多数对抗TNF和维得利珠单抗失败。第24周无激素临床缓解、生化缓解及联合缓解率分别为29%、25%和19%,既往维得利珠单抗暴露与临床缓解降低相关,托法替布相关不良事件发生率为89/100患者年,6%因不良事件停药。

要点

  • 托法替布在抗TNF和维得利珠单抗失败的UC患者中第24周无激素临床缓解率为29%。
  • 既往维得利珠单抗暴露与临床缓解率降低相关(OR 0.33,95%CI 0.11-0.94)。
  • 托法替布相关不良事件发生率为89/100患者年,6%患者因此停药。

核心结论

  • 托法替布是抗TNF和维得利珠单抗失败后UC的有效治疗,但不良事件发生率相对较高,6%患者因此停药。

研究设计与样本

  • 荷兰15家医院前瞻性纳入123例启动托法替布的UC患者,中位随访24周(IQR 12-26)。
  • 95%有抗TNF暴露史,62%有维得利珠单抗暴露史,3%有乌司奴单抗暴露史。
  • 在常规内镜评估的中心评估内镜结局。

主要发现

  • 第24周无激素临床缓解率为29%(22/77),生化缓解率为25%(14/57),无激素临床与生化联合缓解率为19%(11/57)。
  • 第12周内镜缓解(Mayo=0)率为21%(7/33)。
  • 既往维得利珠单抗暴露与临床缓解降低相关(OR 0.33,95%CI 0.11-0.94)。
  • 第24周仍在托法替布治疗的患者中33%(14/42)使用10 mg每日两次。
  • 共发生33例托法替布相关不良事件(89/100患者年),7例(占总数6%)导致停药。

临床怎么用

  • 托法替布可用于抗TNF和维得利珠单抗失败的UC患者,但需关注不良事件及血脂变化。
  • 既往维得利珠单抗暴露者托法替布缓解率可能较低,治疗选择时应考虑。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tofacitinib is a Janus kinase inhibitor approved for the treatment of ulcerative colitis (UC). AIM: To evaluate effectiveness, safety and use of tofacitinib in daily practice. METHODS: UC patients initiating tofacitinib were prospectively enrolled in 15 hospitals in the Netherlands. Corticosteroid-free clinical remission (short clinical colitis activity index [SCCAI] ≤2), biochemical remission (faecal calprotectin level ≤250 µg/g), combined corticosteroid-free clinical and biochemical remission, predictors of remission, safety outcomes, treatment dose and effect on lipids were determined at weeks 12 and 24. Endoscopic outcomes were evaluated in centres with routine endoscopic evaluation. RESULTS: In total, 123 UC patients (95% anti-TNF, 62% vedolizumab and 3% ustekinumab experienced) were followed for a median duration of 24 weeks (interquartile range 12-26). The proportion of patients in corticosteroid-free clinical, biochemical, and combined corticosteroid-free clinical and biochemical remission rate at week 24 was 29% (n: 22/77), 25% (n: 14/57), and 19% (n: 11/57) respectively. Endoscopic remission (Mayo = 0) was achieved in 21% of patients at week 12 (n: 7/33). Prior vedolizumab exposure was associated with reduced clinical remission (odds ratio 0.33, 95% confidence interval [CI] 0.11-0.94). At week 24, 33% (n: 14/42) of patients still on tofacitinib treatment used 10 mg twice daily. In total, 33 tofacitinib-related adverse events (89 per 100 patient years) occurred, 7 (6% of total cohort) resulted in discontinuation. Cholesterol, HDL and LDL levels increased during induction treatment by 18% (95% CI 9-26), 18% (95% CI 8-28) and 21% (95% CI 14-39) respectively. CONCLUSION: Tofacitinib is an effective treatment for UC after anti-TNF and vedolizumab failure. However, a relatively high rate of adverse events was observed resulting in discontinuation in 6% of patients.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Biemans VBC, Sleutjes JAM, de Vries AC, et al. Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry. Aliment Pharmacol Ther. 2020. PMID: 32237087. doi:10.1111/apt.15689

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。